SG Americas Securities LLC Increases Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

SG Americas Securities LLC boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 89.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,085 shares of the company's stock after acquiring an additional 14,644 shares during the period. SG Americas Securities LLC's holdings in Viridian Therapeutics were worth $596,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its holdings in shares of Viridian Therapeutics by 968.3% in the second quarter. Dimensional Fund Advisors LP now owns 107,580 shares of the company's stock valued at $1,400,000 after acquiring an additional 97,510 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Viridian Therapeutics by 430.3% in the 2nd quarter. Squarepoint Ops LLC now owns 142,936 shares of the company's stock valued at $1,860,000 after purchasing an additional 115,980 shares in the last quarter. Millennium Management LLC increased its position in Viridian Therapeutics by 1,014.7% during the 2nd quarter. Millennium Management LLC now owns 228,182 shares of the company's stock worth $2,969,000 after purchasing an additional 207,711 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Viridian Therapeutics by 30.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,687 shares of the company's stock worth $412,000 after buying an additional 7,450 shares in the last quarter. Finally, Algert Global LLC lifted its holdings in shares of Viridian Therapeutics by 46.7% in the 2nd quarter. Algert Global LLC now owns 55,493 shares of the company's stock valued at $722,000 after buying an additional 17,673 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Royal Bank of Canada upped their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. TD Cowen initiated coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They issued a "buy" rating for the company. Wells Fargo & Company restated an "equal weight" rating and set a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Needham & Company LLC reiterated a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Finally, HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Monday, December 16th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $35.70.

Viridian Therapeutics Trading Down 3.5 %

Shares of Viridian Therapeutics stock traded down $0.70 during mid-day trading on Friday, hitting $19.38. 831,383 shares of the stock were exchanged, compared to its average volume of 1,244,399. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -4.50 and a beta of 1.13. Viridian Therapeutics, Inc. has a twelve month low of $11.40 and a twelve month high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a 50-day simple moving average of $19.41 and a 200 day simple moving average of $19.43.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.08 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.